<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Wed, 17 Jun 2026 02:00:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+-+Company+to+present+at+Animal+Longevity+Summit+2026/26655918.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / June 17, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) an emerging leader in the field of longevity research, today</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+-+Company+to+present+at+Animal+Longevity+Summit+2026/26655918.html</guid>
   <pubDate>Wed, 17 Jun 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC - Company to present at Animal Longevity Summit 2026</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+-+Company+to+present+at+Animal+Longevity+Summit+2026/26655918.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / June 17, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) an emerging leader in the field of longevity research, today</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+-+Company+to+present+at+Animal+Longevity+Summit+2026/26655918.html</guid>
   <pubDate>Wed, 17 Jun 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Notice of AGM</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+AGM/26601347.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Notice of Annual General Meeting and Board Changes&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / June 4, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting (&quot;AGM&quot;) at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.&lt;/p&gt;&lt;p&gt;The Notice of the AGM (&quot;Notice&quot;) and Form of Proxy will shortly be available on the Company's website, &lt;a rel=&quot;nofollow&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+AGM/26601347.html</guid>
   <pubDate>Thu, 04 Jun 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Notice of AGM</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Notice+of+AGM/26601347.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Notice of Annual General Meeting and Board Changes&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / June 4, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting (&quot;AGM&quot;) at 11am on Monday 29 June 2026 at One Heddon Street, London, W1B 4BD.&lt;/p&gt;&lt;p&gt;The Notice of the AGM (&quot;Notice&quot;) and Form of Proxy will shortly be available on the Company's website, &lt;a rel=&quot;nofollow&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Notice+of+AGM/26601347.html</guid>
   <pubDate>Thu, 04 Jun 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Exercise+of+Warrants+and+Issue+of+Equity/26456618.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Exercise of Warrants and Issue of Equity&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / May 8, 2026 / &lt;/strong&gt;Genflow (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Exercise+of+Warrants+and+Issue+of+Equity/26456618.html</guid>
   <pubDate>Fri, 08 May 2026 05:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Exercise of Warrants and Issue of Equity</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Exercise+of+Warrants+and+Issue+of+Equity/26456618.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Exercise of Warrants and Issue of Equity&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / May 8, 2026 / &lt;/strong&gt;Genflow (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a biotechnology company focused on the development of gene therapies for age-related diseases announces that it</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Exercise+of+Warrants+and+Issue+of+Equity/26456618.html</guid>
   <pubDate>Fri, 08 May 2026 05:50:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Final Results</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Final+Results/26401811.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 30, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;), an emerging leader in the field of longevity research, focused</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Final+Results/26401811.html</guid>
   <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Final Results</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Final+Results/26401811.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 30, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;), an emerging leader in the field of longevity research, focused</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Final+Results/26401811.html</guid>
   <pubDate>Thu, 30 Apr 2026 09:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements </title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Expansion+of+Confidentiality+Agreements+/26376643.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Plc&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 28, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;),</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Expansion+of+Confidentiality+Agreements+/26376643.html</guid>
   <pubDate>Tue, 28 Apr 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements </title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Expansion+of+Confidentiality+Agreements+/26376643.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Plc&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Expansion of Confidentiality Agreements with Tier-1 Animal Health Companies&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 28, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;),</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Expansion+of+Confidentiality+Agreements+/26376643.html</guid>
   <pubDate>Tue, 28 Apr 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Strategic Technology Collaboration</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Strategic+Technology+Collaboration/26332677.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 20, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European biotechnology company focused on the development of gene therapies for age-related diseases, today announces that it has entered into a strategic technology collaboration with Acuitas Therapeutics (&quot;Acuitas&quot;), a globally recognised leader in lipid nanoparticle (&quot;LNP&quot;) delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Strategic+Technology+Collaboration/26332677.html</guid>
   <pubDate>Mon, 20 Apr 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Strategic Technology Collaboration</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Strategic+Technology+Collaboration/26332677.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt; &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 20, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European biotechnology company focused on the development of gene therapies for age-related diseases, today announces that it has entered into a strategic technology collaboration with Acuitas Therapeutics (&quot;Acuitas&quot;), a globally recognised leader in lipid nanoparticle (&quot;LNP&quot;) delivery systems whose technology has underpinned some of the most commercially successful mRNA therapeutic programmes brought to market</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Strategic+Technology+Collaboration/26332677.html</guid>
   <pubDate>Mon, 20 Apr 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces International Patent Publication</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+International+Patent+Publication/26301664.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 13, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European-based</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+International+Patent+Publication/26301664.html</guid>
   <pubDate>Mon, 13 Apr 2026 02:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces International Patent Publication</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+International+Patent+Publication/26301664.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;International Patent Publication Expands Protection for SIRT6-Based Muscular Disease Program&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / April 13, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European-based</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+International+Patent+Publication/26301664.html</guid>
   <pubDate>Mon, 13 Apr 2026 02:10:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Total Voting Rights</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/26243279.html</link>
   <description>
      &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 31, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) announces that the total issued share capital of the Company as at 31 March 2026 consists of 535,653,205 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 535,653,205.&lt;/p&gt;&lt;p&gt;The figure of 535,653,205 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/26243279.html</guid>
   <pubDate>Tue, 31 Mar 2026 02:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Total Voting Rights</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/26243279.html</link>
   <description>
      &lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 31, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) announces that the total issued share capital of the Company as at 31 March 2026 consists of 535,653,205 ordinary shares of £0.0003 each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 535,653,205.&lt;/p&gt;&lt;p&gt;The figure of 535,653,205 ordinary shares may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their investment</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Total+Voting+Rights/26243279.html</guid>
   <pubDate>Tue, 31 Mar 2026 02:45:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Issue of Equity &amp; PDMR Notifications</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Successful Subscription to Raise £800,000 and PDMR Notifications&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 5, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European-based biotechnology company</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html</guid>
   <pubDate>Thu, 05 Mar 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Issue of Equity &amp; PDMR Notifications</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Successful Subscription to Raise £800,000 and PDMR Notifications&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 5, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European-based biotechnology company</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Issue+of+Equity+%26+PDMR+Notifications/26114913.html</guid>
   <pubDate>Thu, 05 Mar 2026 07:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Result of GM</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Results of General Meeting&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 2, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Proxy Voting Results&lt;/strong&gt;&lt;/p&gt;&lt;table style=&quot;width:100%&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style=&quot;border:1.0pt solid windowtext;padding:0in 5.4pt;width:16.78%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Ordinary Resolutions&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:16.34%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Votes for&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:9.58%;&quot;&gt;&lt;p&gt;&lt;strong&gt;% of votes cast for&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:13.6%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Votes Against&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:11.16%;&quot;&gt;&lt;p&gt;&lt;strong&gt;% of votes cast against&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html</guid>
   <pubDate>Mon, 02 Mar 2026 07:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Result of GM</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;Results of General Meeting&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 2, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or &quot;the Company&quot;) a leading European-based biotechnology company focusing on longevity, is pleased to announce that all resolutions proposed at the General Meeting held earlier today were duly passed by shareholders. The number of proxy votes for each resolution submitted prior to the meeting are presented below.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Proxy Voting Results&lt;/strong&gt;&lt;/p&gt;&lt;table style=&quot;width:100%&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style=&quot;border:1.0pt solid windowtext;padding:0in 5.4pt;width:16.78%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Ordinary Resolutions&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:16.34%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Votes for&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:9.58%;&quot;&gt;&lt;p&gt;&lt;strong&gt;% of votes cast for&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:13.6%;&quot;&gt;&lt;p&gt;&lt;strong&gt;Votes Against&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in 5.4pt;width:11.16%;&quot;&gt;&lt;p&gt;&lt;strong&gt;% of votes cast against&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style=&quot;border-bottom-style:solid;border-color:windowtext;border-left-style:none;border-right-style:solid;border-top-style:solid;border-width:1.0pt;padding:0in</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Result+of+GM/26087151.html</guid>
   <pubDate>Mon, 02 Mar 2026 07:55:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Receipt of First Tranche of Grant</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 2, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html</guid>
   <pubDate>Mon, 02 Mar 2026 02:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Receipt of First Tranche of Grant</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Receipt of First Tranche of €4 Million Non-Dilutive Funding from Wallonia Region for GF-1002 Development&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / March 2, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot;</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Receipt+of+First+Tranche+of+Grant/26085249.html</guid>
   <pubDate>Mon, 02 Mar 2026 02:05:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Plc&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / February 12, 2026 / &lt;/strong&gt;Genflow Biosciences Plc</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html</guid>
   <pubDate>Thu, 12 Feb 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study</title>
   <link>http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Plc&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Positive Preliminary Interim Results from SLAB Clinical Trial of SIRT6 Gene Therapy in Aged Dogs&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / February 12, 2026 / &lt;/strong&gt;Genflow Biosciences Plc</description>
   <guid isPermaLink="true">http://www.streetinsider.com/ACCESS+Newswire/Genflow+Biosciences+PLC+Announces+Preliminary+Interim+Results+From+Dog+Study/25985702.html</guid>
   <pubDate>Thu, 12 Feb 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
  <item>
   <title>Genflow Biosciences PLC Announces Notice of GM</title>
   <link>http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html</link>
   <description>
      &lt;p&gt;&lt;i&gt;&lt;strong&gt;THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Genflow Biosciences Plc&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;strong&gt;Notice of General Meeting&lt;/strong&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;strong id=&quot;dateline&quot;&gt;LONDON, UK / &lt;a href='https://www.accessnewswire.com/'&gt;ACCESS Newswire&lt;/a&gt; / February 11, 2026 / &lt;/strong&gt;Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) (&quot;Genflow&quot; or the &quot;Company&quot;), a European-based biotechnology company focused on</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Genflow+Biosciences+PLC+Announces+Notice+of+GM/25977957.html</guid>
   <pubDate>Wed, 11 Feb 2026 02:00:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">GENFF</category>
   	  </item>
 </channel>
</rss>
